Detalhe da pesquisa
1.
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol
; 19(6): 799-811, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29753703
2.
NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.
Oncologist
; 23(10): 1133-e112, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30076277